Medigene AG (LTS:0QGJ) Total Equity : €19.66 Mil (As of Jun. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Medigene AG Total Equity?

Medigene AG's total equity for the quarter that ended in Jun. 2024 was €19.66 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Medigene AG Total Equity Historical Data

The historical data trend for Medigene AG's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Total Equity Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

81.82

53.15

44.82

37.03

21.07

Medigene AG Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Equity	Get a 7-Day Free Trial															59.14	37.03	30.19	21.07	19.66

Medigene AG Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Medigene AG's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	31.716	-	10.649
	=	21.07

Medigene AG's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2024 )	-	Total Liabilities(Q: Jun. 2024 )
	=	28.81	-	9.15
	=	19.66

Medigene AG Total Equity Related Terms

Thank you for viewing the detailed overview of Medigene AG's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (LTS:0QGJ) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

MDG1:Germany MDG2:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG Headlines

No Headlines